文献速递神经免疫

累积钆双胺暴露致早期多发性硬化脑内钆沉积

Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.
PubMed 文献 · Neurology · 2019-07-08

该回顾性纵向研究纳入203例早期多发性硬化(MS)患者(107例有基线与随访MRI)和262例年龄性别匹配对照,评估终生累积钆双胺剂量与齿状核、苍白球和丘脑信号强度比(SIR)的关联。随访平均55.4个月、平均钆双胺给药9.2次,49.3%的MS患者出现齿状核T1高信号而对照无一人出现(p<0.001)。齿状核与脑桥SIR随钆双胺剂量增加而升高(p<0.001),但未发现其与疾病严重程度的临床或影像学指标相关。

要点

  • 早期MS患者多次接受钆双胺后,齿状核、苍白球和丘脑出现钆沉积相关信号增高。
  • 49.3%的MS患者随访时齿状核T1高信号,对照组无此表现。
  • 齿状核SIR与钆双胺累积剂量相关,但未发现与疾病严重程度相关。

核心结论

  • 早期MS患者齿状核、苍白球和丘脑的钆沉积与终生累积钆双胺给药相关,但未发现与更侵袭性疾病的临床或影像学相关指标。

研究设计与样本

  • 回顾性、纵向、3T MRI读片盲法研究,纳入203例早期MS患者(基线病程<2年,所有MRI时间点仅接受钆双胺)和262例年龄性别匹配对照,其中107例MS患者有基线与随访MRI评估。

主要发现

  • 平均随访55.4个月,平均钆双胺给药9.2次。
  • 随访时49.3%的MS患者出现齿状核T1高信号,对照组无一人出现(p<0.001)。
  • MS患者齿状核与脑桥SIR(p<0.001)及苍白球与脑桥SIR(p=0.005)高于对照。
  • MS患者齿状核、苍白球和丘脑与侧脑室CSF体积的SIR均高于对照(p<0.001)。
  • 齿状核与脑桥SIR与钆双胺给药次数相关(p<0.001),但未发现其与疾病严重程度的临床或MRI结局相关。

临床怎么用

  • 对于早期MS患者,应关注多次使用钆双胺后脑内钆沉积的影像学表现,但现有证据未显示其与疾病严重程度相关。

局限性

  • 本研究为回顾性设计,仅纳入使用钆双胺的早期MS患者,随访时间平均55.4个月,未评估其他钆对比剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Frequent administration of gadolinium-based contrast agents in multiple sclerosis (MS) may increase signal intensity (SI) unenhanced T1-weighted imaging MRI throughout the brain. We evaluated the association between lifetime cumulative doses of gadodiamide administration and increased SI within the dentate nucleus (DN), globus pallidus (GP), and thalamus in patients with early MS. METHODS: A total of 203 patients with MS (107 with baseline and follow-up MRI assessments) and 262 age- and sex-matched controls were included in this retrospective, longitudinal, 3T MRI-reader-blinded study. Patients with MS had disease duration <2 years at baseline and received exclusively gadodiamide at all MRI time points. SI ratio (SIR) to pons and CSF of lateral ventricle volume (CSF-LVV) were assessed. Analysis of covariance and correlation analyses, adjusted for age, sex, and region of interest volume, were used. RESULTS: The mean follow-up time was 55.4 months, and the mean number of gadolinium-based contrast agents administrations was 9.2. At follow-up, 49.3% of patients with MS and no controls showed DN T1 hyperintensity (p < 0.001). The mean SIR of DN (p < 0.001) and of GP (p = 0.005) to pons and the mean SIR of DN, GP, and thalamus to CSF-LVV were higher in patients with MS compared to controls (p < 0.001). SIR of DN to pons was associated with number of gadodiamide doses (p < 0.001). No associations between SIR of DN, GP, and thalamus and clinical and MRI outcomes of disease severity were detected over the follow-up. CONCLUSIONS: DN, GP, and thalamus gadolinium deposition in early MS is associated with lifetime cumulative gadodiamide administration without clinical or radiologic correlates of more aggressive disease.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Zivadinov R, Bergsland N, Hagemeier J, et al. Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology. 2019. PMID: 31285398. doi:10.1212/WNL.0000000000007892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。